购彩中心

TOPIC：Nanostructures Developed as Delivery Carriers to Overcome Tumor Resistance to Cisplatin Therapy
SPEAKER：梁兴杰研究员，国家纳米科学中心
TIME：November 1 (Tuesday)14:00 pm
VENUE：化学B楼410会议室
INVITER：颜德岳教授

Abstract:

Multidrug resistance is one of the main obstacles in the chemotherapeutic failure of malignant metastasis cancer treatments in clinic. Several factors involving in drug resistance include enhanced repair mechanisms of drug induced DNA damage, lowered tumor extracellular pH, alteration of cell cycle check points, blockage of apoptosis pathway, poor tumor vasculature and over expression of drug efflux pumps. Nanotechnology has been widely used in the development of new strategies for drug delivery and cancer therapy. Compared to traditional drug delivery systems, nano-systems have greater potential in many areas, such as multiple targeting functionalization, in vivo imaging, combined drug delivery, longer circulation time and systemic control release. Nano-systems incorporating stimulus-responsive biomaterials have remarkable properties which allow them to bypass biological barriers and achieve targeted intracellular drug delivery. Some of these have been translated from the bench to clinical application and have been approved by the Food and Drug Administration (FDA) for treatment of various cancerous diseases. With further development of reabsorbable nanoscale biomaterials, it might be possible to design even more promising multiple-responsive nano-systems synergestic for drug delivery and cancer therapy in the future. Nanotechnology-based drug delivery is expected to bring new hope for cancer treatment by enhancing anticancer drug efficacy, overcoming drug resistance and reducing drug toxicity. This study describes the characteristic features of tumor resistance to cisplatin chemotherapy and their targeting mechanisms with the aid of nanoparticles for the development of newer drug delivery systems to overcome multidrug resistance in cancer cells.

Biography:

Dr. Xing-Jie Liang got Ph.D at National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences. He finished his postdoc with Dr. Michael M. Gottesman (Deputy Director of NIH, USA) for 5 years at Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Then, he worked as a Research Fellow at Surgical Neurology Branch, NINDS (National Institute of Neurological Diseases and Strokes, NIH) for 2 years. In 2007, he was an Assistant professor at Department of Radiology, School of Medicine, Howard University. Dr. Liang currently is deputy director of Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and a principal investigator at Laboratory of Controllable Nanopharmaceuticals, CAS Center for Excellence in Nanoscience and National Center for Nanoscience and Technology of China. Dr. Liang is a founder member of International Society of Nanomedicine, member of American Association for Cancer Research, American Society of Cell Biology, American Chemical Society, and deputy director of nanoscale biomaterials committees of Chinese Society of Biomaterials and Chinese Society of Micro/Nanoscale Sicene and Technology. Dr. Liang is current Associate Editors of 《Biomaterials》 and《Biophysics Report》;  Advisory editorial board member of 《ACS Nano》;  Editorial member of 《Advances in Nano Research》, 《Current Nanoscience》, 《Biomaterials Research》, 《Theranostics》 and guest editor of 《Biotechnology Advances》.
His research interests are in elucidating mechanisms to improve nanomedicinal bioavailability by nanotechnology in vitro and in vivo, and novel strategies to increase therapeutic efficacy on cancers and infective diseases. Developing drug delivery strategies for prevention/treatment of infective diseases and cancers are current programs ongoing in Dr. Liang\'s lab based on understanding of basic physio-chemical and biological processes of nanomedicine. Most protocols are employed for delivering therapeutic molecules (chemical compounds, peptides or nucleic acids) to actively target cells or tissues in vivo to enhance drug safety and efficacy.